SEC filing record
Primary Source · SEC.gov

AIM ImmunoTech Inc.

2024 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalNew Form D filerForm D · 2024-02-20Last filing 2024-02-20

Raised

$3M

Investors

1

Min Invest

$2,500,000

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

AIM ImmunoTech Inc. is a Delaware corporation that first filed a Form D on September 2, 2016 and most recently amended it on February 21, 2024 in the Biotechnology industry group. The offering claims Rule 506(b) and covers debt. AIM ImmunoTech Inc. reported $3,301,250 sold from 1 investor of a $3,301,250 total offering as of the Form D filed February 21, 2024. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $2,500,000. The Form D names Ascendiant Capital Markets, LLC (CRD 152912), associated with None as the recipient of sales compensation soliciting in UT. Sales commissions are reported as $130,000 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 2117 Sw Highway 484, Ocala, FL 32801.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0000946644
Entity NameAIM ImmunoTech Inc.
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address2117 Sw Highway 484, Ocala, FL 32801
Phone(352) 448-7797
Former NamesAIM ImmunoTech Inc. (until November 17, 2026); HEMISPHERX BIOPHARMA INC (until August 26, 2019)
Industry / Fund TypeBiotechnology
Securities TypeDebt
First Sale DateFebruary 16, 2024
Filing DateFebruary 21, 2024
Accession Number0000946644-24-000002
Total Offering Amount$3,301,250
Total Amount Sold$3,301,250
Amount Remaining$0
Total Investors1
Non-Accredited InvestorsNone
Minimum Investment$2,500,000
Offering DurationOne year or less
Sales Commissions$130,000 (to Ascendiant Capital Markets, LLC)
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)FL
Amendment Count5 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

1

latest Feb 20, 2024

Critical / warning

0 / 0

0 watch · 1 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

4

closed

Latest event New filer · Feb 20, 2024

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 1 filing event with values and deltas, latest 2024-02-20, and alerts on the next one
  • 4 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Thomas Equals

Executive Officer, Director · Ocala, FL

Peter Rodino

Executive Officer · Ocala, FL

Rob Dickey

Executive Officer · Ocala, FL

William Mitchell

Director · Ocala, FL

Stewart Appelrouth

Director · Ocala, FL

Nancy Bryan

Director · Ocala, FL

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Ascendiant Capital Markets, LLCCRD 152912 on BrokerCheck

Associated broker-dealer: None · Jupiter, FL · Soliciting in UT

Questions About AIM ImmunoTech Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is AIM ImmunoTech Inc.?

AIM ImmunoTech Inc. is a Delaware corporation that filed a Form D with the SEC on February 21, 2024 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of debt.

Is AIM ImmunoTech Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. AIM ImmunoTech Inc. filed a Form D with the SEC on February 21, 2024 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $3,301,250 sold to 1 investor. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is AIM ImmunoTech Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that AIM ImmunoTech Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has AIM ImmunoTech Inc. raised?

AIM ImmunoTech Inc. reported $3,301,250 sold from 1 investor of a $3,301,250 total offering as of the Form D filed February 21, 2024.

Who can invest in AIM ImmunoTech Inc.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $2,500,000.

What is the minimum investment in AIM ImmunoTech Inc.?

The Form D lists $2,500,000 as the minimum investment accepted from any outside investor as of February 21, 2024. Issuers can waive their own minimums, and the figure does not include fees.

Who is selling AIM ImmunoTech Inc. and how are they paid?

The Form D names Ascendiant Capital Markets, LLC (CRD 152912), associated with None as the recipient of sales compensation soliciting in UT. Sales commissions are reported as $130,000 and finders' fees as $0. Form D allows these to be estimates.

Who is behind AIM ImmunoTech Inc.?

The Form D lists 6 related persons: Thomas Equals, executive officer, director; Peter Rodino, executive officer; Rob Dickey, executive officer; William Mitchell, director; Stewart Appelrouth, director; Nancy Bryan, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is AIM ImmunoTech Inc. located?

The issuer's address on its SEC filings is 2117 Sw Highway 484, Ocala, FL 32801. Its phone number of record is 352-448-7797. It is organized under the laws of Delaware.

How long is the AIM ImmunoTech Inc. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 1 amendment is on record for this CIK.

What is AIM ImmunoTech Inc.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.